Pfizer Announces an Independent Medical Education Grant RFP

Multidisciplinary Gene Therapy Education Recombinant Adeno-Associated Virus (rAAV)
Competitive Grant Program - internal Pfizer review process

I. BackgroundPfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives(e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet
medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP)
that provides detail regarding a general area of interest, sets timelines for review and approval, and uses
an internal Pfizer review process to make final grant decisions. Organizations are invited to submit anapplication addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) isresponsible for the design, implementation, and conduct of the independent initiative supported by thegrant. Pfizer must not be involved in any aspect of project development, nor the conduct of theindependent education program.

3GeneTherapy Education

II. Eligibility
Geographic Scope:

GlobalApplicant Eligibility
Criteria•

The following may apply: medical, dental, nursing, allied health, and/or
pharmacy professional schools; healthcare institutions (both large andsmall); professional associations and medical societies; medical
education companies; and other entities with a mission related tohealthcare professional education and/or healthcare improvement.

•If the project involves multiple departments within an institution and/orbetween different institutions / organizations / associations, all institutions
must have a relevant role and the requesting organization must have akey role in the project.

III. Requirements
Date RFP Issued

14 July 2022

Clinical Area

Gene Therapy – Rare Disease

General Area ofInterest for this RFP:

•Through this RFP we seek to support educational initiatives that focus on
one or both of the following:oo••

Improving the medical and scientific understanding of recombinantadeno-associated virus (rAAV) gene therapy to help prepare
multidisciplinary teams for the integration of rAAV gene therapy into
the treatment armamentarium of eligible patients with a Rare
DiseaseAdvancing the preparedness of gene therapy centers withinstitutional and/or multidisciplinary team training to execute clinicaland operational best practices (e.g., SOPs and workflows) to
optimize the quality of care for patients who are eligible for available
recombinant adeno-associated virus (rAAV) gene therapies.

Proposals that include/address the following will be prioritized:
oPatient participation in the development of the initiative

oHealth literacy best practices

oDiversity, equity and inclusion considerations

oOmnichannel approaches (an integrated approach between multiple
channels of communication)

Proposals should be related to rAAV gene therapy education that istherapeutic area and disease area agnostic (i.e., not related to a specific3GeneTherapy Education

rare disease or group of rare diseases)•Proposals tailored to a specific rare disease or group of rare diseases will
not be considered.

Target Audience:•Members of multidisciplinary care teams for rAAV gene therapy including
but not limited to Pharmacists, Specialty Nurses, Genetic Counsellors,
Medical Geneticists, and other Physicians, including referring physicians.

Expected Approximate
Monetary Range ofGrant Applications:•Individual projects requesting up to $50,000 USD will be considered.
Pfizer anticipates supporting up to 2 projects.

Key Dates:•

RFP release date: 14 July 2022•

Grant Application due date: 20 September 2022•

Anticipated Grant Award Notification Date: October 2022•

Grants will be distributed following a fully executed agreement. Theagreement is expected to be signed by both parties within 2022 andwithout change.

•Anticipated Project Start Date: on or after January 2023•

Please go to www.cybergrants.com/pfizer/knowledge and sign in. Firsttime users should click “Create your password”.

•In the application:

How to Submit:

oFor the question “What type of request are you submitting?” selectResponse to a Request for Proposal (RFP)

oFor the question “Are you replying to a Request for Proposal as partof the Competitive Grant Program?” select YesoSelect the following Competitive Grant Program Name: 2022 RD G
Gene Therapy EducationoSelect the following Primary Area of Interest: Gene Therapy•Requirements for submission:
Complete all required sections of the online application and upload yourproject proposal (see Appendix) in the General RFP Submission field.

•If you encounter any technical difficulties with the website, please click the“Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not
be reviewed by the committee.

3GeneTherapy Education

Questions:•If you have questions regarding this RFP, please direct them in writing tothe Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with thesubject line “2022 RD G Gene Therapy Education”.

Grant Agreements:•

If your grant is approved, your institution will be required to enter into awritten grant agreement with Pfizer. Please click here to view the coreterms of the agreement.
Pfizer has drafted the terms of these agreements to be balanced andreasonable and to further the goals of both parties. Negotiating grant
agreements requires significant resources, so please ensure that yourinstitution (including your legal department) is able and willing to abide bythese terms before proceeding with submission of your application as
they will need to be accepted in their entirety.

•Review and Approval
Process•

Grant requests received in response to a general RFP are reviewed byPfizer to make final grant decisions.

Mechanism by which
Applicants will be
Notified:••

All applicants will be notified via email by the dates noted above.
Applicants may be asked for additional clarification during the review
period.

3GeneTherapy Education

Appendix A

General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins.
Note there is a 12-page limit exclusive of references. Please include the following:
Goals and Objectives••

Briefly state the overall goal of the project.
List the objectives you plan to meet with your project, in terms of learningand expected outcomes.

Needs Assessment forthe Project•

Include a description of your organization’s needs assessment for this
proposed project which may include a quantitative baseline datasummary, initial metrics, or a project starting point (please cite data on
gap analyses or relevant patient-level data that informs the statedobjectives) in your target area.

Target Audience•Describe the primary audience(s) targeted for this project. Indicate whom
you believe will directly benefit from the project outcomes. Describe theoverall population size as well as the size of your sample population.

Project Design andMethods•

Describe the planned project, the educational approach, and the way theplanned methods address the established need.

Innovation•Explain what measures you have taken to assure that this project isoriginal and does not duplicate other projects or materials alreadydeveloped. Describe how this project builds upon existing work, pilot
projects, or ongoing projects developed either by your institution or otherinstitutions.

Evaluation andOutcomes•In terms of the metrics used for the needs assessment, describe how
your organization will determine if the gap was addressed for the target
group. Identify the sources of data your organization anticipates using to
make the determination. Describe how your organization is expected tocollect and analyze the data. Explain the method used to control for otherfactors outside this project (e.g., use of a control group or comparison
with baseline data). Quantify the amount of change expected from thisproject in terms the target audience. Describe how your organization will
determine if the target audience was fully engaged in the project.

Dissemination Plan•

Describe how the project may have extended benefit beyond the grant.
Will the teaching materials be made available to others to use? Will
there be tools or resources that are made publicly available beyond theinitial project. Describe how the project outcomes might be broadly
disseminated.

3GeneTherapy Education

Anticipated ProjectTimeline•

Provide an anticipated timeline for your project including project start/enddates.

Additional Information•

If there is any additional information you feel Pfizer should be aware ofconcerning the importance of this project, please summarize here.

Organization Detail•

Describe the attributes of the institutions/organizations that will support
and facilitate the execution of the project, the leadership of the proposedproject, and the specific role of each institution in the proposed project.

Budget Narrative•

Please include a budget narrative that describes in greater detail the line
items specified in the budget submitted within the application•While estimating your budget please keep the following items in mind:oo

Independent Medical Education Grants awarded by GMG cannot
be used to purchase therapeutic assets (prescription or nonprescription).
Overhead rates of up to 28% of the total proposed project budget
may be supported by Pfizer. Please click here for details.